Mulpleo (previously Lusutrombopag Shionogi)
Withdrawn
lusutrombopag
MedicineHumanWithdrawn
Czech is available via eTranslation, the European Commission's machine translation service.
Translate to Czech | Important information about machine translation
On 14 April 2026, the European Commission withdrew the marketing authorisation for Mulpleo (lusutrombopag) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Shionogi B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.
Mulpleo was granted marketing authorisation in the EU on 18 February 2019 to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023.
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures